Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
J.P. Morgan Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Announces Target Price $72
Balanced Outlook: Hold Rating on Edwards Lifesciences Amidst Market Uncertainties and Growth Potential
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $83
Deutsche Bank Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $85
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Analysts Are Bullish on These Healthcare Stocks: Liquidia Technologies (LQDA), Edwards Lifesciences (EW)
Piper Sandler Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $73
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)
RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $85
RBC Capital Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Daiwa Securities Upgrades Edwards Lifesciences Outperform From Neutral, Adjusts Price Target to $72 From $87
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)
CICC Research Adjusts Price Target on Edwards Lifesciences to $80 From $105, Maintains Outperform Rating
What 22 Analyst Ratings Have To Say About Edwards Lifesciences
Wolfe Research Upgrades Edwards Lifesciences(EW.US) to Hold Rating
Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
Edwards Lifesciences Price Target Cut to $91.00/Share From $107.00 by Goldman Sachs
Edwards Lifesciences Analyst Ratings